Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Enterprise Value (2016 - 2025)

Altimmune (ALT) has disclosed Enterprise Value for 16 consecutive years, with -$43.8 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 66.77% to -$43.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$43.8 million through Dec 2025, up 66.77% year-over-year, with the annual reading at -$43.8 million for FY2025, 66.77% up from the prior year.
  • Enterprise Value for Q4 2025 was -$43.8 million at Altimmune, up from -$210.8 million in the prior quarter.
  • The five-year high for Enterprise Value was -$31.6 million in Q3 2024, with the low at -$210.8 million in Q3 2025.
  • Average Enterprise Value over 5 years is -$143.3 million, with a median of -$170.0 million recorded in 2021.
  • Peak annual rise in Enterprise Value hit 73.01% in 2025, while the deepest fall reached 567.9% in 2025.
  • Over 5 years, Enterprise Value stood at -$190.4 million in 2021, then increased by 2.87% to -$184.9 million in 2022, then decreased by 7.0% to -$197.9 million in 2023, then skyrocketed by 33.32% to -$131.9 million in 2024, then soared by 66.77% to -$43.8 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$43.8 million, -$210.8 million, and -$183.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.